Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $296 | $252 | $259 | $452 |
| - Cash | $57 | $33 | $24 | $19 |
| + Debt | $60 | $61 | $42 | $31 |
| Enterprise Value | $299 | $280 | $276 | $463 |
| Revenue | $179 | $117 | $120 | $149 |
| % Growth | 53.4% | -2.8% | -19.4% | – |
| Gross Profit | $161 | $110 | $118 | $148 |
| % Margin | 89.6% | 93.9% | 98.5% | 99.3% |
| EBITDA | $29 | -$17 | -$54 | -$11 |
| % Margin | 15.9% | -14.5% | -44.8% | -7.6% |
| Net Income | $17 | -$25 | -$59 | -$18 |
| % Margin | 9.8% | -21.5% | -48.7% | -12% |
| EPS Diluted | 0.99 | -1.44 | -3.4 | -1.1 |
| % Growth | 168.7% | 57.6% | -209.1% | – |
| Operating Cash Flow | $31 | -$6 | -$74 | $6 |
| Capital Expenditures | -$0 | -$15 | -$0 | -$1 |
| Free Cash Flow | $31 | -$21 | -$74 | $5 |